News

May 3, 2021

Tools4Patient Proves Performance of Novel Technology to Predict Placebo Response in Osteoarthritis Clinical Trials

Belgian startup Tools4Patient recently presented data showing its novel technology Placebell©™ predicted placebo response in a Phase 2 randomized controlled trial (RCT) for osteoarthritis (OA). Placebell is the first robust technology using predictive modeling that is proven to reduce the impact of the placebo response in clinical trials under real-world conditions. Data from the Phase 2 RCT, “Predicting the Placebo Response in OA to Improve the Precision of the Treatment Effect Estimation,” was presented as a late-breaking abstract at the OARSI Connect Virtual World Congress on Osteoarthritis on April 29, 2021. This innovation by Tools4Patient is a major advancement for increasing clinical study success and reducing drug development costs and timelines.

News

April 2, 2021

Tools4Patient Adds Quality Assurance Director To Team

The addition of Delphine to T4P’s expanding team reflects the company’s commitment to building and maintaining a robust quality program, which is central to its goal of being a trusted partner providing predictive tools to biopharmaceutical companies. Delphine works with T4P’s operational and scientific groups to support software and clinical-related activities for programs conducted with sponsors or as part of the company’s R&D activities.

News

March 3, 2021

Webinar: Predict placebo response using patient psychology to increase trial power

What if you could predict placebo responsiveness of each patient in your clinical trial? Historical strategies to address the placebo response may help but haven’t completely solved the placebo response problem. Until now. Advanced methods like AI and machine learning are uniquely poised to help scientists uncover the full spectrum of patient placebo responsiveness in a clinical trial. Learn more about this approach by attending our webinar, which explains how a solution like Placebell©™ leverages a time-tested predictive algorithm to improve clinical trial assay sensitivity and de-risk drug development.

News

December 15, 2020

Happy Holidays from our home offices to yours

With 2020 coming to a close, it is an opportune time to pause and reflect on the progress we have made as an industry, as a company and as individuals. We congratulate our partners and friends for their ingenuity and perseverance in rising to the challenges of the year.

News

November 18, 2020

“Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm” published in Pain.

The journal article “Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm”, has been published ahead of print in the journal Pain. This article was authored by Didier Bouhassira, MD, Director of Research at the National Institute for Health and Medical Research (INSERM) in France and member of Tools4Patient’s scientific advisory board, and was co-authored by Tools4Patient scientists Samuel Branders PhD, Alvaro Pereira PhD and Dominique Demolle, PhD.

News

October 20, 2020

The Placebo Response: A Hidden Risk to COVID-19 Trials” – First Opinion written by Tools4Patient authors published in STAT News

STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October…